RITONAVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H48N6O5S2
Molecular Weight	720.944
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H48N6O5S2
Molecular Weight	720.944
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/norvir-drug.htm https://www.drugs.com/mtm/ritonavir.html http://www.wikidoc.org/index.php/Ritonavir

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 2B6 19 Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159797	Inhibitor 8146	2.2 µM [IC50]
Cytochrome P450 3A 22 Target ID: CHEMBL2364675 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10952482	Inhibitor 8146	0.14 µM [IC50]
Human immunodeficiency virus type 1 protease 35 Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17627597	Inhibitor 8146	0.01 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 145 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020659s065,022417s017lbl.pdf	Primary		Approved 8307	NORVIR Approved Use KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology (12.4) and Clinical Studies (14) Launch Date 8.2563839E11

C_max

Value	Dose	Co-administered	Analyte	Population
11.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
129 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020659Orig1s000rev.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		RITONAVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Death fetal... AEs leading to discontinuation/dose reduction: Death fetal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	Other AEs: Gastrointestinal disorder NOS, Lipids abnormal... Other AEs: Gastrointestinal disorder NOS Lipids abnormal Insulin resistance Lipoatrophy Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

AEs

AE	Significance	Dose	Population
Death fetal	1 patient Disc. AE	200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Hypertension	grade 2, 1 patient Disc. AE	50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Co-administed with:: elvitegravir(125 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	healthy, 29 years n = 10 Health Status: healthy Age Group: 29 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Gastrointestinal disorder NOS		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Insulin resistance		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipids abnormal		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/
Lipoatrophy		600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/	unhealthy, adult Health Status: unhealthy Condition: HIV-1 Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/18815591/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670	inducer 372 inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 208 P-gp 1401 CYP2C19 1410 CYP2E1 846 CYP1A2 1463	CYP3A 188 CYP2D 1 CYP3A5 383	CYP3A 125 CYP1A2 671 CYP2C19 283 CYP2B6 521 UGT 28 P-gp 252

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2E1 929	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	no
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2.0	yes [IC50 17.3 uM]	yes (co-administration study) Comment: A published trial (Aarnoutse et al 2005) cited previously published data that reported a 145% increase in desipramine with ritonavir 500 mg twice daily dosing. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 \| https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: 2.0
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 23.5 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/9549640/ Page: -	yes [IC50 6.2 uM]
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP2B6 946	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes
CYP2C19 1484	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes
CYP2C9 1747	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP3A 291	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
CYP3A 291	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes
P-gp 1588	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51.0	yes
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=51 Page: 51.0	yes
UGT 55	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000_ClinPharmR.pdf#page=19 Page: 19.0	yes

Drug as victim

Target	Modality	Activity
CYP3A 188	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	major
CYP3A4 1670	substrate 3264 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.05 uM]
CYP3A5 383	substrate 3264 Sources: https://dmd.aspetjournals.org/content/26/6/552 Page: -	yes [Km 0.21 uM]
CYP2D 1	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020659s013_Norvir_biopharmr.PDF#page=2 Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.sciencedirect.com/science/article/pii/S0140673605179501 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:45409	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45409
ChemicalBook	CB0119429	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0119429
MolPort	MolPort-000-883-877	https://www.molport.com/shop/molecule-link/MolPort-000-883-877
Selleck Chemicals	Ritonavir	http://www.selleckchem.com/products/Ritonavir.html
ZINC	ZINC000003944422	http://zinc15.docking.org/substances/ZINC000003944422
eMolecules	877483	https://www.emolecules.com/cgi-bin/more?vid=877483

PubMed

Title	Date	PubMed
Protease inhibitors shine in triple combinations.	1996 Mar	11363243
Saquinavir soft gelatin capsule: a comparative safety review.	2001	11347724
Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.	2001	11345223
Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.	2001 Apr	11359661
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.	2001 Apr	11312622
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001 Apr	11306154
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.	2001 Apr	11259625
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.	2001 Apr	11257038
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.	2001 Apr 1	11317084
Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.	2001 Apr 10	11350662
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.	2001 Apr 13	11371681
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.	2001 Apr 15	11391173
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.	2001 Apr 15	11391161
Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.	2001 Apr 15	11391159
[An option even for patients with multiple pretreatment].	2001 Apr 2	11373796
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ].	2001 Apr 2	11373795
[Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].	2001 Apr 2	11373793
[Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].	2001 Apr 2	11373769
[No resistance even after 1 year. New drug combination against HIV].	2001 Apr 2	11373766
[Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].	2001 Apr 21	11360738
Antiviral drugs: current state of the art.	2001 Aug	11418355
Pharmacology and clinical experience with saquinavir.	2001 Feb	11336588
Use of HIV protease inhibitors as pharmacoenhancers.	2001 Feb	11279888
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.	2001 Feb	11244316
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.	2001 Jul	11423459
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.	2001 Jun	11422025
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.	2001 Jun	11422019
Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.	2001 Jun 1	11404537
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.	2001 Jun 1	11343221
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.	2001 Jun 15	11417878
Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.	2001 Jun 15	11416725
The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.	2001 Jun 15	11396919
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).	2001 Jun 15	11372025
A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.	2001 Mar	11396754
The safety and antiviral effect of protease inhibitors in children.	2001 Mar	11253853
Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.	2001 Mar 26	11309224
[HIV: a guide on management of seropositive patients].	2001 Mar 3	11268903
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.	2001 Mar 30	11317012
Lopinavir/ritonavir.	2001 Mar-Apr	11296724
Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.	2001 May	11377177
Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.	2001 May	11322888
P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.	2001 May	11297905
A potential role for interleukin-7 in T-cell homeostasis.	2001 May 15	11342421
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.	2001 May 25	11399984
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.	2001 May 25	11399983
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.	2001 May 25	11399982
[Effective in HIV: dual combination with indinavir and ritonavir].	2001 May 4	11381644
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.	2001 May 5	11393736

Patents

Sample Use Guides

In Vivo Use Guide

600 mg twice-day with meals. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Ritonavir diminished the growth rate of Candida albicans as well as the activity of its secreted aspartyl proteinases (Saps) in a nitrogen-limited medium, yeast carbon base and bovine serum albumin (YCB-BSA). This inhibition occurred in a dose-dependent fashion; with 8 mg/l of ritonavir a partial growth inhibition (44%) was produced.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:15:19 UTC 2022` Edited by `admin` on `Fri Dec 16 17:15:19 UTC 2022`
Record UNII	O3J8G9O825
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RITONAVIR

Official Name

English

NORVIR

Brand Name

English

RITONAVIR [VANDF]

Common Name

English

RITONAVIR [MI]

Common Name

English

VIRITON

Brand Name

English

EMPETUS

Brand Name

English

PAXLOVID COMPONENT RITONAVIR

Brand Name

English

ritonavir [INN]

Common Name

English

ABBOTT-84538

Code

English

VIEKIRAX COMPONENT RITONAVIR

Brand Name

English

RITOVIR

Brand Name

English

KALETRA COMPONENT RITONAVIR

Common Name

English

RITONAVIR [HSDB]

Common Name

English

RITONAVIR [USP-RS]

Common Name

English

NSC-693184

Code

English

ABT-538

Code

English

RITONAVIR COMPONENT OF VIEKIRAX

Brand Name

English

RTV

Common Name

English

RITONAVIR [EMA EPAR]

Common Name

English

RITONAVIR [JAN]

Common Name

English

Ritonavir [WHO-DD]

Common Name

English

RITONAVIR COMPONENT OF KALETRA

Common Name

English

RITONAVIR [ORANGE BOOK]

Common Name

English

RITONAVIRUM [WHO-IP LATIN]

Common Name

English

A-84538

Code

English

RITOMUNE

Brand Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE

Common Name

English

2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-

Systematic Name

English

RITONAVIR [MART.]

Common Name

English

2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-

Common Name

English

RITONAVIR [USP IMPURITY]

Common Name

English

RITONAVIR [USP MONOGRAPH]

Common Name

English

RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]

Common Name

English

RITONAVIR [WHO-IP]

Common Name

English

VIEKIRAX

Brand Name

English

5-Thiazolylmethyl [(?S)-?-[(1S,3S)-1-hydroxy-3-[(2S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutyramido]-4-phenylbutyl]phenethyl]carbamate

Common Name

English

RITONAVIR [USAN]

Common Name

English

Classification Tree Code System Code

LIVERTOX

NBK548747